Background
Methods
Data analysis
Results
All patients | Females (20) | Males (28) |
p
| |
---|---|---|---|---|
Age at onset | 56.5 ± 10 | 58.4 ± 12 | 55.2 ± 8.4 | 0.4 |
Age at interview | 62.7 ± 10.6 | 65.4 ± 12 | 60.8 ± 9.2 | 0.3 |
Disease Duration | 6.2 ± 4.2 | 6.8 ± 4.4 | 5.7 ± 4.2 | 0.2 |
Onset | ||||
Tremor | 32/48 (66.7%) | 13/20 (65%) | 19/28 (68%) | 0.8 |
Rigid-akinetic | 16/48 (33.3%) | 7/20 (35%) | 9/28 (32%) | |
UPDRS-I | 2.3. ± 2.1 | 2.4 ± 2.1 | 2.3 ± 2.2 | 0.9 |
UPDRS-II | 9.8 ± 7.1 | 9.5 ± 6.6 | 10 ± 7.0 | 0.9 |
UPDRS-III | 17. 1 ± 11.4 | 16.6 ± 8.7 | 17.5 ± 13.7 | 0.8 |
UPDRS tot | 29.3 ± 20.1 | 29 ± 17.9 | 29.6 ± 21.9 | 0.9 |
LED | 518.4 ± 398.5 | 496. 4 ± 411.8 | 534.2 ± 402.4 | 0.7 |
Levodopa | 354.6 ± 329.3 | 343.4 ± 309.8 | 352.6 ± 347. 9 | 0.8 |
Dopa agonists | 169.9 ± 129.8 | 152. 9 ± 130.3 | 182.1 ± 131.8 | 0.4 |
PDSS | 112. 9 ± 22 | 113.8 ± 25.6 | 112.3 ± 19.3 | 0.8 |
MMSE | 28 ± 2 | 28.2 ± 2.2 | 28 ± 2.0 | 0.6 |
BDI | 9 ± 7 | 9.7 ± 7 | 8.4 ± 7.1 | 0.5 |
NPI | 10.7 ± 9.5 | 11.4 ± 10.3 | 9.9. ± 8.9 | 0.6 |
SCOPA-AUT tot | 14.1 ± 6.9 | 15.1 ± 6.3 | 13.5 ± 7.4 | 0.4 |
SCOPA-U subscores | 5.2 ± 3.8 | 4.8 ± 3.6 | 5.5 ± 4.4 | 0.5 |
Maximum flow rate | 17.9 ± 9.1 | 21.9 ± 12 | 15.4 ± 6 | 0.03 |
Postvoid residual | 24.4 ± 44.2 | 18.9 ± 44.4 | 28.3 ± 44.4 | 0.5 |
SCOPA-AUT total | Females | Males | SCOPA-U subscore | Females | Males | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
ρ di Pearson |
p
| ρ di Pearson |
p
| ρ di Pearson |
p
| ρ di Pearson |
p
| ρ di Pearson |
p
| ρ di Pearson |
p
| |
Age at interview | 0.22 | 0.13 | 0.034 | 0.90 | 0.35 | 0.07 | 0.41 | 0.003 | 0.48 | 0.03 | 0.43 | 0.02 |
Disease duration | 0.20 | 0.18 | 0.06 | 0.80 | 0.27 | 0.17 | 0.08 | 0.60 | −0.009 | 0.10 | 0.16 | 0.4 |
UPDRS-III | 0.39 | 0.006 | 0.45 | 0.05 | 0.38 | 0.04 | 0.27 | 0.06 | 0.52 | 0.02 | 0.17 | 0.38 |
UPDRS tot | 0.40 | 0.005 | 0.41 | 0.07 | 0.40 | 0.04 | 0.26 | 0.07 | 0.46 | 0.04 | 0.16 | 0.41 |
LED | 0.27 | 0.06 | 0.09 | 0.71 | 0.40 | 0.04 | 0.21 | 0.15 | 0.25 | 0.29 | 0.18 | 0.36 |
Levodopa | 0.30 | 0.03 | 0.09 | 0.70 | 0.43 | 0.02 | 0.21 | 0.14 | 0.25 | 0.30 | 0.19 | 0.33 |
Dopa agonists | −0.028 | 0.85 | 0.06 | 0.81 | −0.06 | 0.78 | 0.10 | 0.94 | 0.18 | 0.45 | −0.11 | 0–57 |
PDSS | −0.46 | 0.001 | −0.50 | 0.02 | −0.037 | 0.05 | 0.12 | 0.41 | −0.55 | 0.01 | −0.08 | 0.67 |
BDI | 0.31 | 0.03 | 0.34 | 0.14 | 0.29 | 0.13 | 0.14 | 0.35 | 0.37 | 0.1 | 0.01 | 0.95 |
NPI | 0.35 | 0.01 | 0.37 | 0.10 | 0.32 | 0.09 | 0.23 | 0.12 | 0.30 | 0.2 | 0.23 | 0.24 |
PDQ-39 | ||||||||||||
Mobility | 0.34 | 0.02 | 0.31 | 0.20 | 0.34 | 0.08 | 0.29 | 0.04 | 0.54 | 0.01 | 0.20 | 0.31 |
Social supp | 0.15 | 0.30 | 0.12 | 0.61 | 0.19 | 0.33 | −0.17 | 0.24 | 0.28 | 0.24 | −0.01 | 0.96 |
Stigma | 0.22 | 0.13 | − 0.029 | 0.90 | 0.37 | 0.05 | 0.18 | 0.21 | −0.21 | 0.63 | 0.41 | 0.03 |
Daily activity | 0.28 | 0.06 | 0.90 | 0.70 | 0.40 | 0.04 | 0.26 | 0.08 | 0.27 | 0.26 | 0.25 | 0.20 |
Well-being | 0.22 | 0.1 | 0.28 | 0.23 | 0.16 | 0.41 | 0.63 | 0.67 | 0.30 | 0.20 | −0.04 | 0.82 |
Communication | 0.30 | 0.04 | 0.26 | 0.36 | 0.34 | 0.08 | 0.14 | 0.34 | 0.27 | 0.25 | 0.7 | 0.73 |
Cognition | 0.37 | 0.01 | 0.27 | 0.25 | 0.41 | 0.03 | 0.30 | 0.04 | 0.44 | 0.05 | 0.24 | 0.22 |
Bodily discomfort | 0.26 | 0.08 | 0.40 | 0.09 | 0.14 | 0.47 | 0.04 | 0.76 | 0.11 | 0.64 | 0.05 | 0.79 |
Qmax | −0.23 | 0.14 | −0.47 | 0.06 | −0.22 | 0.27 | −0,26 | 0.09 | −0.51 | 0.04 | −0.08 | 0.70 |
PVR | 0.036 | 0.80 | 0.10 | 0.66 | 0.1 | 0.99 | 0.13 | 0.40 | 0.18 | 0.45 | 0.07 | 0.73 |